Literature DB >> 6347119

Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.

J M Kane, A Rifkin, M Woerner, G Reardon, S Sarantakos, D Schiebel, J Ramos-Lorenzi.   

Abstract

In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1.25 to 5.0 mg/2 wk) with the standard-dose regimen (12.5 to 50.0 mg/2 wk) in outpatient schizophrenics. For the first 126 patients studied, cumulative relapse rates at one year for the low dose were 56% and for the standard dose 7%, a significant difference. Despite the fact that very little dyskinetic symptomatology developed in the sample as a whole, the low-dose treatment appeared to have a significant advantage in producing fewer early signs of tardive dyskinesia. Severity of relapse and total cumulative dosage were also considered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6347119     DOI: 10.1001/archpsyc.1983.01790070083010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  33 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

3.  Commentary: consensus statement on negative symptoms.

Authors:  John Kane
Journal:  Schizophr Bull       Date:  2005-10-12       Impact factor: 9.306

4.  Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

Authors:  Hiroyoshi Takeuchi; Takefumi Suzuki; Gary Remington; Robert R Bies; Takayuki Abe; Ariel Graff-Guerrero; Koichiro Watanabe; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Bull       Date:  2013-07-01       Impact factor: 9.306

5.  Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.

Authors:  Hiroyuki Uchida; Takefumi Suzuki; Hiroyoshi Takeuchi; Tamara Arenovich; David C Mamo
Journal:  Schizophr Bull       Date:  2009-11-27       Impact factor: 9.306

Review 6.  A tipping point in drug dosing in late-life schizophrenia.

Authors:  Takashi Tsuboi; Takefumi Suzuki; Hiroyuki Uchida
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

Review 7.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

Review 8.  Review: treatment of schizophrenia. State of the art.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

9.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

10.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.